Skip Navigation

Products developed with Acura's proprietary Aversion® Technology are intended to deter or discourage common methods of prescription drug abuse:

  • Intentionally swallowing excess quantities of tablets
  • Crushing and nasally snorting tablets
  • Injecting dissolved tablets with a syringe

dr.home

Lead Product

Acurox® (oxycodone HCl/niacin) is an immediate release tablet product for pain relief utilizing Aversion® Technology. The New Drug Application for Acurox® Tablets is under review by the US Food and Drug Administration with a Priority review classification and a June 30, 2009 FDA targeted action date.



Collaboration

Acura has entered into a license agreement with King Pharmaceuticals, Inc. to develop and commercialize opioid analgesic products utilizing our proprietary Aversion® Technology, including Acurox® Tablets.


Innovation

Acura’s strategy includes continued investment in novel solutions to prescription drug abuse. We have three issued U.S. patents covering our Aversion® Technology with numerous US and international patent applications pending.